Role of SHIP in cancer

Experimental Hematology

Volumn 39, Issue 1, 2011, Pages 2-13

  Hamilton, Melisa J ^a   Ho, Victor W ^a   Kuroda, Etsushi ^a,b   Ruschmann, Jens ^a,c   Antignano, Frann ^a,d   Lam, Vivian ^a   Krystal, Gerald ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AQX 100 MN; AQX MN 100; BCR ABL PROTEIN; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; MICRORNA; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; SH2 DOMAIN CONTAINING PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 5 PHOSPHATASE; STAT3 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BASOPHIL; CANCER CELL CULTURE; CARCINOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; ENZYME LOCALIZATION; HEMATOPOIETIC CELL; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOSTIMULATION; INHIBITION KINETICS; LEUKEMIA; LEUKEMOGENESIS; LYMPHOMA; MACROPHAGE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN CONFORMATION;

EID: 78650191420     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.11.002     Document Type: Review

References (117)

1. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009, 102:19-65.
2. Ho V, Hamilton M, Kuroda E, et al. SHIP and tumor-associated macrophages. In: Lawrence T, and Hagemann T, eds. Tumour-Associated Macrophages. New York: Springer, In press.
3. Sly L.M., Rauh M.J., Kalesnikoff J., Buchse T., Krystal G. SHIP, SHIP2 and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is upregulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 2003, 31:1170-1181.
4. Gewinner C., Wang Z.C., Richardson A., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
5. 2 levels determine PKB activity. Cell Signal 2008, 20:684-694.
6. 2 is required for PKB phosphorylation at Ser473. Studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 2002, 277:9027-9035.
7. Zhang T.T., Li H., Cheung S.M., et al. Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation. Immunol Rev 2009, 232:255-272.
8. Antignano F., Ruschmann J., Hamilton M., et al. The Src homology 2 containing inositol 5′ phosphatases. Handbook of Cell Signalling 2009, 1065-1084. Elsevier Inc, San Diego. R.A. Bradsaw, E.A. Dennis (Eds.).
9. Costinean S., Sandhu S.K., Pedersen I.M., et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ- MiR-155 transgenic mice. Blood 2009, 114:1374-1382.
10. Lo T.C., Barnhill L.M., Kim Y., Nakae E.A., Yu A.L., Diccianni M.B. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res 2009, 33:1562-1566.
11. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 2009, 106:7113-7118.
12. Pedersen I.M., Otero D., Kao E., et al. Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas. EMBO Mol Med 2009, 1:288-295.
13. Yamanaka Y., Tagawa H., Takahashi N., et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009, 114:3265-3275.
14. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
15. Prasad N.K., Tandon M., Badve S., Snyder P.W., Nakshatri H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008, 29:25-34.
16. Prasad N.K., Tandon M., Handa A., et al. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol 2008, 29:330-341.
17. Leslie N.R., Batty I.H., Maccario H., Davidson L., Downes C.P. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008, 27:5464-5476.
18. Bunney T.D., Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010, 10:342-352.
19. Harris S.J., Parry R.V., Westwick J., Ward S.G. Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem 2008, 283:2465-2469.
20. Parry R.V., Harris S.J., Ward S.G. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. Biochim Biophys Acta 2010, 1804:592-597.
21. Kerr W.G. A role for SHIP in stem cell biology and transplantation. Curr Stem Cell Res Ther 2008, 3:99-106.
22. Sasaoka T., Wada T., Tsuneki H. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 2006, 112:799-809.
23. Astle M.V., Horan K.A., Ooms L.M., Mitchell C.A. The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors?. Biochem Soc Symp 2007, 74:161-181.
24. Yogo K., Mizutamari M., Mishima K., et al. Src homology 2 (SH2)-containing 5′-inositol phosphatase localizes to podosomes, and the SH2 domain is implicated in the attenuation of bone resorption in osteoclasts. Endocrinology 2006, 147:3307-3317.
25. Hitomi K., Tahara-Hanaoka S., Someya S., et al. An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. Nat Immunol 2010, 11:601-607.
26. Peng Q., Malhotra S., Torchia J.A., Kerr W.G., Coggeshall K.M., Humphrey M.B. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal 2010, 3:ra38.
27. Pesesse X., Backers K., Moreau C., et al. SHIP1/2 interaction with tyrosine phosphorylated peptides mimicking an immunoreceptor signalling motif. Adv Enzyme Regul 2006, 46:142-153.
28. Ong C.J., Ming-Lum A., Nodwell M., et al. Small molecule agonists of SHIP inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 2007, 110:1942-1949.
29. Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., Lucas D.M. Structure, function, and biology of SHIP proteins. Genes Dev 2000, 14:505-520.
30. Song M., Kim M.J., Ha S., Park J.B., Ryu S.H., Suh P.G. Inositol 5′-phosphatase, SHIP1 interacts with phospholipase C-γ1 and modulates EGF-induced PLC activity. Exp Mol Med 2005, 37:161-168.
31. Wisniewski D., Strife A., Swendeman S., et al. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5- phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 1999, 93:2707-2720.
32. Geier S.J., Algate P.A., Carlberg K., et al. The human SHIP gene is differentially expressed in cell lineages of the bone marrow and blood. Blood 1997, 89:1876-1885.
33. Ono M., Bolland S., Tempst P., Ravetch J.V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc-γ RIIB. Nature 1996, 383:263-266.
34. Ruschmann J., Ho V., Antignano F., et al. Tyrosine phosphorylation of SHIP promotes its proteasomal degradation. Exp Hematol 2010, 38:393-402.
35. Damen J.E., Liu L., Ware M.D., Ermolaeva M., Majerus P.W., Krystal G. Multiple forms of SHIP are generated by C-terminal truncation. Blood 1998, 92:1199-1205.
36. Horn S., Meyer J., Heukeshoven J., et al. The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro. Leukemia 2001, 15:112-120.
37. Kavanaugh W.M., Pot D.A., Chin S.M., et al. Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2. Curr Biol 1996, 6:438-445.
38. Tu Z., Ninos J.M., Ma Z., et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein. Blood 2001, 98:2028-2038.
39. Damen J.E., Liu L., Rosten P., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc Natl Acad Sci U S A 1996, 93:1689-1693.
40. Lioubin M.N., Algate P.A., Tsai S., Carlberg K., Aebersold A., Rohrschneider L.R. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev 1996, 10:1084-1095.
41. Collazo M.M., Wood D., Paraiso K.H., et al. SHIP limits immunoregulatory capacity in the T-cell compartment. Blood 2009, 113:2934-2944.
42. Helgason C.D., Damen J.E., Rosten P., et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998, 12:1610-1620.
43. Leung W.H., Tarasenko T., Bolland S. Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes. Immunol Res 2009, 43:243-251.
44. Liu Q., Oliveira-Dos-Santos A.J., Mariathasan S., et al. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J Exp Med 1998, 188:1333-1342.
45. Tarasenko T., Kole H.K., Chi A.W., Mentink-Kane M.M., Wynn T.A., Bolland S. T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci U S A 2007, 104:11382-11387.
46. Oh S.Y., Zheng T., Bailey M.L., et al. Src homology 2 domain-containing inositol 5-phosphatase 1 deficiency leads to a spontaneous allergic inflammation in the murine lung. J Allergy Clin Immunol 2007, 119:123-131.
47. Haddon D.J., Antignano F., Hughes M.R., et al. SHIP is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo. J Immunol 2009, 183:228-236.
48. Takeshita S., Namba N., Zhao J.J., et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 2002, 8:943-949.
49. Wahle J.A., Paraiso K.H., Costello A.L., Goll E.L., Sentman C.L., Kerr W.G. Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol 2006, 176:7165-7169.
50. Fortenbery N.R., Paraiso K.H., Taniguchi M., Brooks C., Ibrahim L., Kerr W.G. SHIP influences signals from CD48 and MHC class I ligands that regulate NK cell homeostasis, effector function, and repertoire formation. J Immunol 2010, 184:5065-5074.
51. Wang J.W., Howson J.M., Ghansah T., et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002, 295:2094-2097.
52. Ghansah T., Paraiso K.H., Highfill S., et al. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol 2004, 173:7324-7330.
53. + T cell development. J Immunol 2006, 176:3958-3965.
54. Kim C.H., Hangoc G., Cooper S., et al. Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest 1999, 104:1751-1759.
55. Mason J.M., Halupa A., Hyam D., et al. Ship-1 regulates the proliferation and mobilization of the erythroid lineage [abstract]. Blood 2002, 100:519a. Abstract 2030.
56. Perez L.E., Desponts C., Parquet N., Kerr W.G. SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors. PLoS One 2008, 3:e3565.
57. Maeda K., Mehta H., Drevets D.A., Coggeshall K.M. IL-6 increases B cell IgG production in a feed-forward pro-inflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 2010, 115:4699-4706.
58. Nakamura K., Kouro T., Kincade P.W., Malykhin A., Maeda K., Coggeshall K.M. Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow. J Exp Med 2004, 199:243-254.
59. Charlier E., Conde C., Zhang J., et al. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity. Leukemia 2010, 24:821-832.
60. Locke N.R., Patterson S.J., Hamilton M.J., Sly L.M., Krystal G., Levings M.K. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 2009, 183:975-983.
61. Rauh M.J., Ho V., Pereira C., et al. SHIP represses the generation of alternatively activated macrophages. Immunity 2005, 23:361-374.
62. + regulatory T cells, which suppress via membrane-bound TGFβ-1. J Immunol 2008, 181:2220-2226.
63. Paraiso K.H.T., Ghansah T., Costello A., Engelman R.W., Kerr W.G. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 2007, 178:2893-2900.
64. Lakhanpal G.K., Vecchiarelli-Federico L.M., Li Y.J., et al. The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood 2010, 116:428-436.
65. Alinikula J., Kohonen P., Nera K.P., Lassila O. Concerted action of Helios and Ikaros controls the expression of the inositol 5-phosphatase SHIP. Eur J Immunol 2010, 40:2599-2607.
66. Rebollo A., Schmitt C. Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol 2003, 81:171-175.
67. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
68. Luo J.M., Yoshida H., Komura S., et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003, 17:1-8.
69. Luo J.M., Liu Z.L., Hao H.L., Wang F.X., Dong Z.R., Ryuzo O. Mutation analysis of SHIP gene in acute leukemia. Zhonghua Xue Ye Xue Za Zhi 2004, 25:385-388.
70. Horn S., Endl E., Fehse B., Weck M.M., Mayr G.W., Jucker M. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3β signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004, 18:1839-1849.
71. Fukuda R., Hayashi A., Utsunomiya A., et al. Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci U S A 2005, 102:15213-15218.
72. Jiang X., Stuible M., Chalandon Y., et al. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 2003, 102:2976-2984.
73. Martino R., Caballero M.D., Canals C., et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001, 115:653-659.
74. Vanderwinden J.M., Wang D., Paternotte N., Mignon S., Isozaki K., Erneux C. Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT. Cell Signal 2006, 18:661-669.
75. Sly L.M., Rauh M.J., Kalesnikoff J., Song C.H., Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004, 21:227-239.
76. Cuschieri J., Bulger E., Grinsell R., Garcia I., Maier R.V. Insulin regulates macrophage activation through Activin A1. Shock 2007, 29:285-290.
77. Sattler M., Salgia R., Shrikhande G., et al. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene 1997, 15:2379-2384.
78. Cao L., Yu K., Banh C., et al. Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 2007, 179:5864-5876.
79. Cremer T.J., Ravneberg D.H., Clay C.D., et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS One 2009, 4:e8508.
80. McCoy C.E., Sheedy F.J., Qualls J.E., et al. IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem 2010, 285:20492-20498.
81. Ruggiero T., Trabucchi M., De Santa F., et al. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J 2009, 23:2898-2908.
82. Androulidaki A., Iliopoulos D., Arranz A., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231.
83. Kohlhaas S., Garden O.A., Scudamore C., Turner M., Okkenhaug K., Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009, 182:2578-2582.
84. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
85. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
86. Henderson W.R., Chi E.Y., Jong E.C., Klebanoff S.J. Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med 1981, 153:520-533.
87. Maltby S., Khazaie K., McNagny K.M. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009, 1796:19-26.
88. Crivellato E., Nico B., Ribatti D. Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett 2008, 269:1-6.
89. Hebda P.A., Collins M.A., Tharp M.D. Mast cell and myofibroblast in wound healing. Dermatol Clin 1993, 11:685-696.
90. Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996, 3:895-904.
91. Johansson A., Rudolfsson S., Hammarsten P., et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010, 177:1031-1041.
92. Okayama Y., Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006, 34:97-115.
93. Alvarez-Errico D., Yamashita Y., Suzuki R., et al. Functional analysis of Lyn kinase A and B isoforms reveals redundant and distinct roles in FcεRI-dependent mast cell activation. J Immunol 2010, 184:5000-5008.
94. Gottfried E., Kreutz M., Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008, 19:65-77.
95. Smits E.L., Anguille S., Cools N., Berneman Z.N., Van Tendeloo V.F. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009, 20:1106-1118.
96. Neill L., Tien A.H., Rey-Ladino J., Helgason C.D. SHIP-deficient mice provide insights into the regulation of dendritic cell development and function. Exp Hematol 2007, 35:627-639.
97. Antignano F., Ibaraki M., Kim C., et al. SHIP is required for dendritic cell maturation. J Immunol 2010, 184:2805-2813.
98. Antignano F., Ibaraki M., Ruschmann J., Jagdeo J., Krystal G. SHIP negatively regulates Flt3L-derived dendritic cell generation and positively regulates MyD88-independent TLR-induced maturation. J Leukoc Biol 2010, 88:925-935.
99. Sinha P., Clements V.K., Miller S., Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005, 54:1137-1142.
100. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
101. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
102. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
103. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
104. Kuroda E., Ho V., Ruschmann J., et al. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J Immunol 2009, 183:3652-3660.
105. Varin A., Gordon S. Alternative activation of macrophages: immune function and cellular biology. Immunobiology 2009, 214:630-641.
106. Sokol C.L., Medzhitov R. Role of basophils in the initiation of Th2 responses. Curr Opin Immunol 2010, 22:73-77.
107. 2 production in murine peritoneal macrophages and splenocytes in response to Candida albicans. Res Microbiol 2005, 156:115-118.
108. Brant K.A., Fabisiak J.P. Nickel alterations of TLR2-dependent chemokine profiles in lung fibroblasts are mediated by COX-2. Am J Respir Cell Mol Biol 2008, 38:591-599.
109. Siracusa M.C., Perrigoue J.G., Comeau M.R., Artis D. New paradigms in basophil development, regulation and function. Immunol Cell Biol 2010, 88:275-284.
110. MacDonald S.M., Vonakis B.M. Association of the Src homology 2 domain-containing inositol 5' phosphatase (SHIP) to releasability in human basophils. Mol Immunol 2001, 38:1323-1327.
111. MacGlashan D.W. Relationship between spleen tyrosine kinase and phosphatidylinositol 5′ phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 2007, 119:626-633.
112. Crabbe T., Welham M.J., Ward S.G. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci 2007, 32:450-456.
113. + cells from patients with acute myeloid leukemia after gene transfer of INPP5D. Gene Ther 2009, 16:570-573.
114. Yang L., Williams D.E., Mui A., et al. Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP. Organic Lett 2005, 7:1073-1076.
115. Kennah M., Yau T.Y., Nodwell M., et al. Activation of SHIP via a small molecule agonist kills multiple myeloma cells experimental hematology. Exp Hematol 2009, 37:1274-1283.
116. Brooks R., Fuhler G.M., Iyer S., et al. SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol 2010, 184:3582-3589.
117. Metzner A., Horstmann M.A., Fehse B., et al. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Gene Ther 2007, 14:699-703.